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OBJECTIVES: Describe primary care physicians’ decision to prescribe antidepressants
to older patients with depression. METHODS: Electronic medical record notes from 
ofﬁ ce visits of older patients (age q 65), treated in a multi-specialty medical group 
practice located in central Massachusetts, were screened bi-weekly for mention of 
depression from August 2007 to July 2008. Electronic surveys inquiring about depres-
sion severity and onset, and antidepressant treatment recommendations were sent to
treating physicians until a target sample of approximately 400 responses was reached. 
Patient characteristics and treatment were identiﬁ ed from administrative claims. Uni-
variate analyses were used to describe patient characteristics and physician survey 
responses. RESULTS: The majority of the 396 patients whose physicians responded 
to the survey and conﬁ rmed depression were female (76.5%), on average 77 years
old; 66.7% had age 65–80 years. Most patients had physician-reported depression 
onset after age 60 (72.2%) and moderately severe depression (58.8%). Physicians
reported that 62.9% of patients were already treated with antidepressants at time of 
screening, 28.5% were recommended antidepressant initiation, and 8.6% were not 
prescribed antidepressants; the rate of patients who were not prescribed antidepres-
sants was similar in patients age 65–80 and over 80 years. SSRIs were most frequently
prescribed. Maintaining prior therapy was recommended for 81.1% of patients and 
treatment modiﬁ cation for 18.9%. Almost all physicians agreed that experience in use
of drugs, safety/tolerability, and patient improvement inﬂ uenced their choice to main-
tain prior therapy or recommend new therapy (92%). 85.8% of physicians agreed
that availability of efﬁ cacy data in the elderly inﬂ uenced their decision to prescribe
new therapy. A total of 38.9% of patients recommended new therapy initiation did 
not ﬁ ll a prescription. CONCLUSIONS: The majority of older patients with depres-
sion are prescribed antidepressants, mostly receiving a recommendation to maintain 
prior therapy. Over two thirds of patients who were recommended new antidepressant
therapy did not ﬁ ll a prescription.
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OBJECTIVES: To investigate the off-label prescribing rates of antidepressants among
ofﬁ ce-based physicians and hospital outpatient department clinics during 2003–2005.
METHODS: The National Ambulatory Medical Care Survey (NAMCS) and the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) were used as data 
sources. Patients who received an antidepressant during the study period were included
in the study. Corresponding diagnosis were analyzed to identify off-label prescribing 
based on Physician Desk Reference and Micromedex. Binary Logistic Regression 
Analysis was used to predict off-label use on the basis of patient’s demographic char-
acteristics and payment methods. Microsoft Access and SPSS 14 were used to analyze
the data. RESULTS: From 2003 to 2005, a total of 172,489 patient records were col-
lected, of which, 12,251 patient records were included in the study. A total of 7,068 
(57.6%) out of 12,251 antidepressant prescriptions were identiﬁ ed as off-label pre-
scriptions in the 3 years. There were 21 different antidepressants were identiﬁ ed in the
databases. Amitriptyline HCl, a TCA/SNRI, had the highest off-label prescription rate
among all the antidepressants. According to patient demographics characteristics, the
odds of receiving antidepressants off-label were found to be increased with age, elderly 
adult patients are 2 to 4 times (OR  3.241, 95% CI  2.727–3.852) more likely to
get an off-label prescription of antidepressants than children/adolescents. Whites were 
considered 1.2 times more likely to receive an off-label prescription of antidepressant
than non-whites (OR  1.218, 95% CI  1.090–1.361) and 71.7 % Medicare patients
were received off-label antidepressant prescription. CONCLUSIONS: Off-label pre-
scribing of antidepressants is highly prevalent, especially in TCA/SNRI class of antide-
pressants. White elderly adults were more likely to get off-label prescriptions than 
non-whites adults. Future studies are required to address the questions of legal, clinical 
and economic aspects of off-label prescribing of antidepressants.
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OBJECTIVES: The study compared medication adherence and time to discontinuation
in patients newly initiated on a second generation anti-psychotic (SGA) in health plans 
with either open or restricted access to antipsychotic medications. Restricted access
included preferred formularies, prior authorization, and electronic step-therapy edits.
METHODS: A retrospective analysis was performed using claims from a large phar-
macy beneﬁ t management company. The company provides pharmacy beneﬁ ts for 
health plans with a variety of open versus restricted pharmacy beneﬁ t designs. Con-
tinuously enrolled commercially insured patients newly initiating atypical antipsy-
chotic therapy between January 1, 2004 and February 28, 2007 were identiﬁ ed and 
followed for 13 months or until index medication discontinuation. Adherence, deﬁ ned
by medication possession ratio (MPR), was calculated as the ratio of total days’ supply 
of medication to total days to discontinuation or end of the follow-up period. Patients
with a calculated MPR  80% were deﬁ ned as adherent. Discontinuation was deﬁ ned 
as a gap of 30 days, switch, or add-on of another antipsychotic. Regression models 
were used to compare adherence and discontinuation in patients with open vs. 
restricted access while controlling for gender, copayment, index dosage, and co-mor-
bidity. RESULTS: A total of 8128 patients were included in the study. Of these, 7226 
(88.9%) were from health plans with no SGA restrictions. The results showed that 
patients with open access were signiﬁ cantly more likely to be adherent (OR  1.38, 
95% CI: 1.14–1.66), and signiﬁ cantly less likely to discontinue (OR  0.88, 95% CI:
0.81–0.95), than patients with restricted access. CONCLUSIONS: Patients in health 
plans with restricted access to SGAs were less likely to be adherent and more likely 
to discontinue when compared to patients with open access to these medications. Since
low adherence to SGAs is associated with increased likelihood of inpatient hospitaliza-
tion, restricted access to antipsychotics may ultimately result in poor patient outcomes
and higher overall health care costs.
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OBJECTIVES: Bipolar Disorder (BPD) and depression are associated with a broad 
burden of illness which may affect as much as 6% of the U.S. population. In the 
STAndards for BipoLar Excellence (STABLE) project we developed speciﬁ c perfor-
mance measures for BPD and, as part of this project we determined the knowledge, 
attitudes and beliefs about depression and BPD among primary care (PCP) and psy-
chiatric specialty care (PSCP) providers. Additionally, we ﬁ eld-tested performance
measures in a geographically diverse sampling of PCP and PSCP practices to assess 
actual practice. METHODS: A questionnaire was administered to a random selection
of PCPs and PSCPs to determine their knowledge, attitudes and beliefs about bipolar 
disorder. Selected clinical performance measures were subsequently evaluated through
medical record review of 80 outpatient practice sites (the providers at these sites did
not necessarily participate in the KABP survey). Partial results are shown here. 
RESULTS: A total of 95.3% of the KABP survey respondents believed recognizing 
bipolar disorder was their responsibility (98.6% of PSCPs, 91.1% of PCPs). Addition-
ally, 87.6% of the KABP respondents believed that they routinely assessed depression
and BPD patients for substance abuse (98.2% of PSCPs and 73.7% of PCPs). In the
ﬁ eld testing phase of the project, (through medical record review) we found that only 
47.6% documented BPD screening prior to treatment of depression (62.8% of PSCPs
and 38.4% of PCPs). Forty-one percent (78.1% PSCPs vs. 18.1% of PCPs) docu-
mented screening for substance abuse among depressed patients and 78.3% (87% 
PSCPs vs. 37.8% PCPs) document substance abuse screening in their BPD patients. 
CONCLUSIONS: While providers demonstrated awareness of assessment and treat-
ment guidelines for depression and BPD, appraisal of actual physician practices did 
not conform to KABP survey results. These observations provide an opportunity to 
improve care through professional organizations and health plans, and require differ-
ent approaches than just guideline dissemination.
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OBJECTIVES: The objective of this study was to investigate whether patients with
comorbid anxiety and depression have greater health care utilization than patients with
depression alone. METHODS: Data was collected from The 2003 Medical Expendi-
ture Panel Survey (MEPS), a nationally representative survey of the United States non-
institutionalized population. The study sample which included 2196 adults (older than 
age 18) with depression (ICD-9-CM  311) was identiﬁ ed from The 2003 Full Year 
Consolidated Data and Medical Conditions File. Health care utilization and health
care expenditures of individuals with depression and anxiety (ICD-9-CM  300) were 
compared to individuals with depression but without anxiety. All analyses and esti-
mates were accounted for complex sample design of MEPS by using SUDAAN v 10.0. 
Wald chi-square tests to examine the association among categorical variables while 
Student’s t-tests were performed to assess differences of health care expenditures. 
RESULTS: Of the 2196 adults with depression, 18.2% had comorbid anxiety. The 
average total health care expenditure of depressed patients with anxiety was $9432, 
which is signiﬁ cantly higher than that of depressed patients without anxiety, $6006 (p 
 0.01). Total expenditure of prescriptions was signiﬁ cantly different between depressed
patients with and without anxiety ($2868 vs. $1636, p  0.01). Mean number of 
prescriptions was signiﬁ cantly higher in patients with comorbid anxiety (38 vs. 23, 
p  0.01). A higher number of ofﬁ ce-based physician visits was found in the group of 
patients with anxiety (10.3 vs. 6.1, p  0.01). Mean expenditure of ofﬁ ce-based physi-
cian visits for patients with and without anxiety are $1347 and $777, respectively (p
 0.01). CONCLUSIONS: When comorbid anxiety existed among depressed patients, 
health care utilization and health care expenditures were signiﬁ cantly higher than those
without comorbid anxiety. Policy makers and health care researchers should consider 
the impact of comorbid anxiety on patients with depression.
